Copyright
©The Author(s) 2022.
World J Clin Oncol. Jan 24, 2022; 13(1): 39-48
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.39
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.39
Table 2 Retrospective studies published within the last decade investigating the impact of locoregional treatment to the primary tumor site in de novo metastatic breast cancer
Ref. | n | Treatment | Patient | Median follow-up (mo) | Outcomes |
Ma et al[35] | 987 | Surgery (n = 463) | Surgery arm: More T1-2, HR-positive, solitary metastasis, bone only metastasis | NR | Median survival (mo): 45 vs 28, P < 0.001 |
No surgery (n = 524) | |||||
Better survival in surgery after systemic therapy than primary surgery | |||||
Triple negative, brain metastases: No benefit of surgery | |||||
Lane et al[16] (NCDB) | 24015 | Systemic therapy alone (n = 13505) | Surgery after systemic therapy arm: Younger, more T3-4 and HR-negative | NR | Median OS (mo): 37.5 vs 49.4 vs 52.8, P < 0.001 |
Surgery before systemic therapy (n = 4552) | RT: No impact on OS | ||||
Systemic therapy before surgery (n = 5958) | |||||
Li et al[36] (SEER database) | 20870 | Surgery (n = 5779) | Surgery arm: Younger, more T1-3, N+, Gr III, and less HR+ | NR | Surgery arm (± RT): Improved BCSS and OS (P < 0.001) |
No surgery (n = 15091) | |||||
More chemo and RT received | |||||
Pons-Tostivint et al[37] | 4276 | LRT (n = 1706): Surgery, RT or both | LRT arm: Younger, more solitary or bone-only metastases | 45.3 | Median OS (mo): HR-positive, HER2- negative: 61.6 vs 45.9, P < 0.001 |
No LRT (n = 2570) | HR-positive, HER2-positive: 77.2 vs 52.6, P = 0.008 | ||||
Triple negative: 19 vs 18.6, P = 0.54 | |||||
Bone only metastases: 70.4 vs 62, P < 0.001 | |||||
Visceral metastases: 83 vs 52.7, P < 0.001 | |||||
Choi et al[38] | 245 | LRT (n = 82): Surgery, RT or both | LRT arm: < T4, no liver or brain metastasis, and < 5 metastatic sites | 40 | 5-yr LRFS: 62% vs 20%, P < 0.001 |
5-yr OS:73% vs 45%, P = 0.02 | |||||
No LRT (n = 163) | |||||
Gultekin et al[7] | 227 | LRT (n = 188): Surgery, RT or both | LRT arm: Less T3-4 and more solitary metastases | 35 | 5-yr OS: 56% vs 24%, P < 0.001 |
5-yr PFS: 27% vs 7%, P < 0.0001 | |||||
No LRT (n = 39) | |||||
Nguyen et al[39] | 733 | LRT (n = 378): Surgery, RT or both | LRT arm: Younger, more T1-2, N0-1, limited M1 disease | 21 | 5-yr OS: 21% vs 14%, P < 0.001 |
5-yr PFS 72% vs 46%, P < 0.001 | |||||
No LRT (n = 355) | |||||
Neuman et al[25] | 186 | Surgery (n = 69): 13% RT | Surgery arm: More HER2-negative, smaller tumors, more solitary metastasis | 52 | No difference in OS (P = 0.10) |
No surgery (n = 117) |
- Citation: Beduk Esen CS, Gultekin M, Yildiz F. Role of radiotherapy in oligometastatic breast cancer: Review of the literature. World J Clin Oncol 2022; 13(1): 39-48
- URL: https://www.wjgnet.com/2218-4333/full/v13/i1/39.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i1.39